Skip to main content
. 2014 Aug 11;111(34):12538–12543. doi: 10.1073/pnas.1408805111

Fig. 4.

Fig. 4.

Repeated donepezil and RS86 treatment prevent the muscarinic receptor-mediated potentiation of NR2B-containing NMDAR responses. NMDAR responses were evoked by ejecting NMDA (1 mM) through a pipette to the patched cells at 1-min intervals and were recorded in CA1 pyramidal cells of naive (A and B), donepezil-exposed (C), and RS86-treated (D) rats. The time course of the effects of indicated drugs on the amplitude of NMDA responses is shown as percentage changes (mean ± SEM) in the peak amplitude of NMDAR responses. Representative traces of NMDA responses recorded before and 20 min (A) or 2 min (B–D) after drug application are shown. (A) Effects of the NR2A-selective antagonist NVP-AAM077 (50 nM, Upper) or the NR2B-selective antagonist ifenprodil (Ifen, 3 μM, Lower) on NMDA responses. (B) Effect of bath application of carbachol (CCh; 10 μM) on NR2B-containing NMDAR-mediated responses (recorded in the presence of NVP-AAM077, Upper) and NR2A-containing NMDAR-mediated responses (recorded in the presence of Ifen, Lower). (C) Effect of bath application of CCh (10 μM) on NMDAR-mediated responses in pyramidal cells of donepezil-exposed rats. (D) Effect of bath application of CCh (10 μM) on NMDAR-mediated responses in pyramidal cells of RS86-treated rats. *P < 0.05.